Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Masayuki Kurosaki
Observed names:
M. Kurosaki,
M., Kurosaki
Institution:
Musashino Red Cross Hospital
Observed institution:
Musashino Red Cross Hospital
ORCID:
0000-0001-7016-8931
Observed ORCID:
0000-0001-7016-8931
OpenAlex ID:
A5137146407
Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma
2016
·
Ming-Chih Ho
, Kiyoshi Hasegawa
, et al.
·
Liver Cancer
·
46
PDF
Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan
2026
·
Hironori Ochi
, Masayuki Kurosaki
, et al.
·
Hepatology Research
·
4
Leucine-Rich Alpha-2 Glycoprotein Is an Accurate Serum Marker for Endoscopic and Histological Remission in Ulcerative Colitis
2026
·
Ami Kawamoto
, Toshimitsu Fujii
, et al.
·
Inflammatory Intestinal Diseases
·
1
PDF
73MO Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study
2022
·
Y.J. Kim
, M. Kurosaki
, et al.
·
Annals of Oncology
·
1
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
2026
·
Chiaki Maeyashiki
, Nobuharu Tamaki
, et al.
·
Journal of Clinical Medicine
Clinical significance of neutrophil-to-lymphocyte ratio dynamics during cabozantinib therapy in unresectable hepatocellular carcinoma.
2026
·
Kaoru Tsuchiya
, Yutaka Yasui
, et al.
·
Journal of Clinical Oncology
Time-toxicity of first-line systemic therapy for hepatocellular carcinoma in clinical practice.
2026
·
Kenta Takaura
, Kaoru Tsuchiya
, et al.
·
Journal of Clinical Oncology
A machine learning algorithm for optimizing treatment selection for patients with up to three hepatocellular carcinomas measuring ≤ 3 cm.
2026
·
Takashi Kokudo
, Yasuhide Yamada
, et al.
·
Journal of Clinical Oncology
Real-world outcomes of combination immunotherapy in patients with Child–Pugh class B hepatocellular carcinoma.
2026
·
Yudai Yamazaki
, Kaoru Tsuchiya
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
10
Citation count:
53
H-index:
2
I10-index:
1
Year
Topic
Type